To unlock this feature and to subscribe to our weekly evidence emails, please create a FREE orthoEvidence account.


Already Have an Account?

Visit our Evidence-Based Covid-19 Website and Stay Up to Date with the latest Research.
Vol:5 Issue:5 Number:8 ISSN#:2564-2537
ACE Report #8932
Ace Report Cover Metabolic Disorders

WCO-IOF 2016: Denosumab versus zoledronic acid following oral bisphosphonate therapy

How to Cite

OrthoEvidence. WCO-IOF 2016: Denosumab versus zoledronic acid following oral bisphosphonate therapy. ACE Report. 2016;5(5):8. Available from:

Study Type:Randomized Trial
OE Level Evidence:N/A
Journal Level of Evidence:N/A

A randomized double-blind study of denosumab (DMAB) compared with zoledronic acid (ZOL) in postmenopausal women with osteoporosis previously treated with oral bisphosphonates

Contributing Authors:
P Miller N Pannacciulli JP Brown E Czerwinski BS Nedergaard MA Bolognese J Malouf HG Bone JY Reginster A Singer C Wang RB Wagman SR Cummings

Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here


This ACE Report is a summary of a conference presentation or abstract. The information provided has limited the ability to provide an accurate assessment of the risk of bias or the overall quality. Please interpret the results with caution as trials may be in progress and select results may have been presented.


643 postmenopausal women with osteoporosis who had been administered oral bisphosphonates for 2 or more years prior to enrollment were randomized to be administered either denosumab or zoledronic acid. The purpose of this study was to compare the change in bone mineral density (BMD) and bone turnover markers after 1 year. Results demonstrated a significantly greater percent increase in BMD - inclu...

Ace Report Preview Image
CME Image

Continuing Medical Education Credits

You could be earning 0.5 CME credits for each report you read.

For Reprints and Permissions, click here

Please Login or Join to leave comments.